You are here
P2D, INC
UEI: KX3EAX2JEMV8
# of Employees: 2
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
MELATONIN ANALOG FOR JET LAG
Amount: $353,001.00DESCRIPTION (provided by applicant): Phase 2 Discovery is developing a synthetic melatonin analog (PD6735) for the treatment of jet lag. No medications are currently approved by the FDA for treatment ...
SBIRPhase I2005Department of Health and Human Services National Institutes of Health -
Thiothalidomides as neuroprotectants drugs for ALS
Amount: $238,026.00DESCRIPTION (provided by applicant): The goal of this Phase 1 SBIR proposal is to identify lead drug candidates from a library of tumor necrosis factor a (TNF-alpha) inhibitors for treating amyotrophi ...
SBIRPhase I2005Department of Health and Human Services National Institutes of Health -
COCAINE THERAPEUTIC: PD2005 DOPAMINE TRANSPORT INHIBITOR
Amount: $136,520.00DESCRIPTION (provided by applicant): The National Institute of Drug Abuse has indicated, "NIDA's top research priority is to find a medication to block or greatly reduce the effects of cocaine to be u ...
SBIRPhase I2004Department of Health and Human Services National Institutes of Health -
A Human Antibody as an Immunotherapy for Cocaine Abuse
Amount: $127,142.00DESCRIPTION (provided by applicant): Despite an understanding of the pharmacological basis of cocaine abuse there is no effective pharmacotherapy, suggesting that pharmacotherapy may be impractical. A ...
SBIRPhase I2004Department of Health and Human Services National Institutes of Health -
Melatonin Analog for Sleep Disorders
Amount: $967,444.00DESCRIPTION (PROVIDED BY APPLICANT): Phase 2 Discovery is developing a synthetic melatonin analog (PD6735) for the treatment of sleep disorders. PD6735 is being developed as a safe and effective trea ...
SBIRPhase II2003Department of Health and Human Services National Institutes of Health -
Biomarker of Neuroprotectant Efficacy in ALS
Amount: $119,065.00DESCRIPTION (provided by applicant): The objective of this Phase I feasibility study is to develop a reliable biomarker of neuronal damage in a validated mouse model of amyotrophic lateral sclerosis ( ...
SBIRPhase I2003Department of Health and Human Services National Institutes of Health -
Serum C-tau Precition of Brain Damage in Mild TBI
Amount: $128,601.00DESCRIPTION (provided by applicant): The objective of the present Phase 1 feasibility study is to develop a quantitative serum-based biomarker for detecting neuronal damage in mild traumatic brain inj ...
SBIRPhase I2003Department of Health and Human Services National Institutes of Health -
NEUROTOXIN DISCOVERY PLATFORM- DRUGS OF ABUSE
Amount: $0.00DESCRIPTION (provided by applicant): The objective of this Phase II application is to develop a sensitive quantitative biomarker of drug-induced neuronal degeneration, particularly associated with dru ...
SBIRPhase I2002Department of Health and Human Services National Institutes of Health -
NEUROTOXIN DISCOVERY PLATFORM- DRUGS OF ABUSE
Amount: $740,914.00DESCRIPTION (provided by applicant): The objective of this Phase II application is to develop a sensitive quantitative biomarker of drug-induced neuronal degeneration, particularly associated with dru ...
SBIRPhase II2002Department of Health and Human Services National Institutes of Health -
BIOMARKER OF NEUROPROTECTANT EFFICACY
Amount: $100,000.00The objective of this Phase I feasibility study is to develop a sensitive biomarker for quantifying neuroprotectant drug efficacy in a rat model of traumatic brain injury (TBI). Currently, no widely a ...
SBIRPhase I2002Department of Health and Human Services National Institutes of Health
